JPMorgan raises Junshi Biosciences rating to neutral

Published 16/05/2025, 06:02
JPMorgan raises Junshi Biosciences rating to neutral

On Friday, JPMorgan analyst Yang Huang upgraded the stock rating of Shanghai Junshi Biosciences Co Ltd (1877:HK) to Neutral from Underweight, while also increasing the price target to HK$12.00 from the previous HK$11.00. This adjustment comes in the wake of the company’s first-quarter results for 2025 and subsequent discussions with Junshi’s management.

The analyst highlighted the strong performance of Junshi’s product toripalimab, a PD-1 inhibitor, in the Chinese market, noting that its sales have surpassed expectations in recent quarters. Despite this positive sales momentum, Huang expressed a cautious outlook due to the uncertainty surrounding the timing of key data readouts, which could serve as significant drivers for the stock’s performance.

The upgrade to a Neutral rating reflects a change in stance towards the company’s Hong Kong-listed stock, known as Junshi-H. However, JPMorgan maintains an Underweight rating on the A-shares of the company, referred to as Junshi-A, citing valuation concerns.

The new price target set by JPMorgan suggests a modest increase in the valuation of Junshi Biosciences’ shares. The firm’s decision to upgrade the stock rating is based on recent financial results and the company’s current market position, as well as the potential for future growth as indicated by the company’s management.

Investors and market watchers will likely monitor Junshi Biosciences closely to see if the company can continue its sales momentum and provide clarity on the anticipated data that could influence its stock value in the near term.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.